A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment
复制标题
一项针对一线治疗失败的 IIIb-IV 期非小细胞肺癌患者进行的多西他赛与多西他赛和伊立替康的随机 II 期试验
作者：
F. Wachters;Hendricus Groen;B. Biesma;Fmnh Schramel;P. E. Postmus;J. Stigt;E. F. Smit
比较多西紫杉醇(75 mg m−2)和多西紫杉醇、伊立替康、来诺斯汀(分别为60 mg m−2、200 mg m−2和150 μg m−2 day−1)二线治疗IIIb-IV期非小细胞肺癌的疗效和毒性。在多西紫杉醇的基础上加用伊立替康并不能提高有效率，反而会增加胃肠道毒性。
Response rate and toxicity of second-line therapy with docetaxel (75 mg m−2) or docetaxel, irinotecan, and lenogastrim (60 mg m−2, 200 mg m−2, and 150 μg m−2 day−1, respectively) were compared in 108 patients with stage IIIb–IV non-small-cell lung cancer. Addition of irinotecan to docetaxel does not improve response rate, and increases gastrointestinal toxicity.
影响因子：
158.5
作者：
Schiller, JH;Harrington, D;Johnson, DH
通讯作者：
Johnson, DH